Category Archives: Global

Sunny Outlook for Outsourcing

Early-stage and mid-size bio/pharmaceutical companies have enjoyed an embarrassment of riches over the past 18 months. The window for initial public offerings (IPOs) re-opened, at least for a while. Global bio/pharmaceutical companies continued their frenzied pace of partnering and acquisition activity, and venture capital spiked up as the prospects improved for rich exits. The results […]
Also posted in Guest Blog | Tagged , , | Leave a comment

Healthcare Reform in China: A Doubled-Edge Sword for Foreign Firms?

The Chinese market is attractive to foreign investors for many reasons. It is the world’s third largest market for pharmaceuticals with annual sale of US$71 billion.  In fact, it is poised to become the second largest market in 2015 given that its annual growth rate of sales is between 15 and 20%, according to Yanzhong […]
Also posted in Biotech, Emerging Markets, Guest Blog, healthcare, Regulatory | Tagged , | Leave a comment

Drugmaker Trains “Diabetes Ambassadors” in Africa

German drugmaker Merck KGaA has begun the second year of its five-year project to provide diabetes management courses for medical and pharmacy students in African Universities. The Merck Capacity Advancement Program (CAP) will be provided at the Universities of Nairobi, Makerere, Uganda, and Namibia, before moving to Tanzania and Ghana. Merck is also offering every healthcare provider in […]
Also posted in Corporate Responsibility, Emerging Markets, healthcare | Leave a comment

The Transatlantic Trade and Investment Partnership: From Hot TTIP to Oblivion?

Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and US economies — and ease conditions for drug firms on both sides of the ocean. TTIP, the Transatlantic Trade and Investment Partnership, was the hot tip for a 2014 success story. But as summer […]
Also posted in Europe | Tagged , , , , , | Leave a comment

Major Changes to EU Clinical Trials Regulation

Earlier this year, the newly approved EU Clinical Trials regulation (No 536/2014) was published in the Official Journal of the EU (OJEU).  The European Commission (EC) estimates that all the changes could save researchers €800 million (over $1 billion) a year. It replaces the existing EU Clinical Trials Directive (2001/20/EC), which was intended to simplify […]
Also posted in Europe, Guest Blog, R&D, Regulatory | Tagged , , , , | Leave a comment
  • Categories

  • Meta